20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action
Open Access
- 5 February 2008
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 98 (4), 792-802
- https://doi.org/10.1038/sj.bjc.6604227
Abstract
We recently isolated 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol (25-OCH3-PPD), a natural product from Panax notoginseng, and demonstrated its cytotoxicity against a variety of cancer cells. Here we report the effects of this compound in vitro and in vivo on human prostate cancer cells, LNCaP (androgen-dependent) and PC3 (androgen-independent), in comparison with three structurally related ginsenosides, ginsenoside Rh2, ginsenoside Rg3, and 20(S)-protopanaxadiol. Of the four test compounds, 25-OCH3-PPD was most potent. It decreased survival, inhibited proliferation, induced apoptosis, and led to G1 cell cycle arrest in both cell lines. It also decreased the levels of proteins associated with cell proliferation (MDM2, E2F1, cyclin D1, and cdks 2 and 4) and increased or activated pro-apoptotic proteins (cleaved PARP, cleaved caspase-3, -8, and -9). In LNCaP cells, 25-OCH3-PPD inhibited the expression of the androgen receptor and prostate-specific antigen. Moreover, 25-OCH3-PPD inhibited the growth of prostate cancer xenograft tumours. Combining 25-OCH3-PPD with conventional chemotherapeutic agents or with radiation led to potent antitumour effects; tumour regression was almost complete following administration of 25-OCH3-PPD and either taxotere or gemcitabine. 25-OCH3-PPD also demonstrated low toxicity to noncancer cells and no observable toxicity in animals. In conclusion, our preclinical data indicate that 25-OCH3-PPD is a potential therapeutic agent against both androgen-dependent and androgen-independent prostate cancer.Keywords
This publication has 51 references indexed in Scilit:
- Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trialsNature Clinical Practice Oncology, 2006
- Androgen Receptor Remains Critical for Cell-Cycle Progression in Androgen-Independent CWR22 Prostate Cancer CellsThe American Journal of Pathology, 2006
- Rh2 Synergistically Enhances Paclitaxel or Mitoxantrone in Prostate Cancer ModelsJournal of Urology, 2006
- Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinomaBiochemical and Biophysical Research Communications, 2006
- Molecular markers of prostate cancer outcomeEuropean Journal Of Cancer, 2005
- Endocrine treatment of prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- MDM2 Is a Negative Regulator of p21 , Independent of p53Journal of Biological Chemistry, 2004
- Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP + -affected mesencephalic dopaminergic cellsJournal of Neural Transmission, 2004
- Inhibitory Effects of Ginsenoside Rh2 on Tumor Growth in Nude Mice Bearing Human Ovarian Cancer CellsJapanese Journal of Cancer Research, 1998
- Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaPThe Prostate, 1993